WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops novel anticancer therapeutics using its
antibody-drug conjugate (ADC) technology, today announced that it has
been named one of The Boston Globe's Top Places to Work. The Company has
received this recognition for the second consecutive year and in three
of the last four years.
Daniel Junius, President and CEO, commented, "We are extremely pleased
that ImmunoGen has once again been recognized as one of The Boston
Globe's Top Places to Work. We believe that attracting and retaining the
right employees is essential to achieving our mission of making a
difference to patients with cancer."
The Boston Globe's 2014 Top Places to Work survey, conducted by
WorkplaceDynamics, measured responses of employees from numerous
organizations in Massachusetts to statements regarding six key factors
related to employee happiness, including company direction, execution,
employee connection, work load and responsibility, management, and pay
and benefits. More than 73,500 individuals responded to the survey.
Among survey respondents, greatest importance was placed on aspects
related to employee appreciation, confidence and feeling a meaningful
connection to the work. WorkplaceDynamics also found that, of all the
cities surveyed, employees in the Boston area were most enthusiastic
about their companies, making Boston the top of the Top Places to Work.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media